Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/37458
Tipo
ArtículoDerechos de autor
Acceso abierto
Fecha del embargo
2020-11-28
Colecciones
- INI - Artigos de Periódicos [3460]
Metadatos
Mostrar el registro completo del ítem
NOVEL EPICARDIAL OFF-PUMP DEVICE FOR MITRAL REGURGITATION: ACUTE EVALUATION
Autor
Afiliación
Cleveland Clinic. Lerner Research Institute. Department of Biomedical Engineering. Cleveland, OH, USA.
Cleveland Clinic. Lerner Research Institute. Department of Biomedical Engineering. Cleveland, OH, USA.
Cleveland Clinic. Department of Cardiovascular Medicine, Heart & Vascular Institute. Cleveland, OH, USA.
Cleveland Clinic. Lerner Research Institute. Department of Biomedical Engineering. Cleveland, OH, USA.
Cleveland Clinic. Lerner Research Institute. Department of Biomedical Engineering. Cleveland, OH, USA.
MAQUET Cardiovascular LLC. San Jose, CA, USA.
MAQUET Cardiovascular LLC. San Jose, CA, USA.
Cleveland Clinic. Lerner Research Institute. Department of Biomedical Engineering. Cleveland, OH, USA.
Cleveland Clinic. Lerner Research Institute. Department of Biomedical Engineering. Cleveland, OH, USA.
Cleveland Clinic. Department of Cardiovascular Medicine, Heart & Vascular Institute. Cleveland, OH, USA.
Cleveland Clinic. Lerner Research Institute. Department of Biomedical Engineering. Cleveland, OH, USA.
Cleveland Clinic. Lerner Research Institute. Department of Biomedical Engineering. Cleveland, OH, USA.
MAQUET Cardiovascular LLC. San Jose, CA, USA.
MAQUET Cardiovascular LLC. San Jose, CA, USA.
Cleveland Clinic. Lerner Research Institute. Department of Biomedical Engineering. Cleveland, OH, USA.
Resumen en ingles
Objective: This study evaluates the ability of a novel epicardial annuloplasty device Mitral Touch (MAQUET Cardiovascular LLC, San Jose, CA, USA) to reduce functional mitral regurgitation (MR) in a rapid ventricular pacing-induced dilated cardiomyopathy model in dogs. Methods: A median sternotomy was performed in 13 dogs after MR induction by rapid ventricular pacing (230 beats/min for an average of 35.6 +/- 12.8 days).
Two-dimensional epicardial echocardiographic and haemodynamic measurements were performed to evaluate the baseline MR grade, the septal—lateral (S—L) dimension of the mitral annulus, mitral valve (MV) geometry and left ventricular function. The Mitral Touch was implanted by sliding the anterior arm onto the floor of the transverse sinus and positioning the posterior arm just apical to the atrioventricular groove on the left ventricular posterolateral wall. The 24-mm-long device was implanted in eight dogs, the 27-mm-long device in four and the 30-mm standard length device in one. MR grade, S—L dimension and haemodynamics data acquisition were immediately rechecked after device implantation. Results: All implantations, which took only approximately 30 s to deploy, were performed on beating hearts without cardiopulmonary bypass. In one early case, after extended manipulation with undersized devices, an atrial laceration was created and bleeding occurred. Design changes were made to eliminate this complication. The MR grade was significantly (p = 0.003) reduced from 3.1 +/- 1.1 at baseline to 1.4+/- 0.8 after device implantation. The S—L dimension at end of systole was also significantly ( p = 0.001) reduced from 2.7 0.4 cm at baseline to 2.3 +/- 0.3 cm after device implantation (% reduction: 15.1+/- 10.6%). The mitral valve coaptation length was significantly (p = 0.0001) increased from 0.36+/- 0.11 cm to 0.50 0.08 cm, and the mitral valve tethering area was significantly (p = 0.0003) decreased from 1.36+/- 0.38 cm2 to 0.81+/- 0.29 cm2 after mitral touch implantation. Conclusions: This new epicardial device was effective in significantly reducing MR and S—L dimensions acutely on the beating heart without requiring the use of cardiopulmonary bypass. Further studies are necessary to confirm the long-term maintenance of MR and S—L reductions.
Compartir